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Abstract
Background: Recent guidelines for the management of hypertension focus on treating patients
according to their global cardiovascular risk (CVR), rather than strictly keeping blood pressure, or
other risk factors, below set limit values. The objective of this study is to compare the effect of a
simple versus a complex educational intervention implementing this new concept among General
Practitioners (GPs).
Methods/design: A prospective longitudinal cluster-randomised intervention trial with 94
German GPs consecutively enroling 40 patients each with known hypertension. All GPs then
received a written manual specifically developed to transfer the global concept of CVR into daily
General Practice. After cluster-randomisation, half of the GPs additionally received a clinical
outreach visit, with a trained peer discussing with them the concept of global CVR referring to
example study patients from the respective GP. Main outcome measure is the improvement of
calculated CVR six months after intervention in the subgroup of patients with high CVR (but no
history of cardiovascular disease), defined as 10-year-mortality ≥ 5% employing the European
SCORE formula. Secondary outcome measures include the intervention's effect on single risk
factors, and on prescription rates of drugs targeting CVR. All outcome measures are separately
studied in the three subgroups of patients with 1. high CVR (defined as above), 2. low CVR (SCORE
< 5%), and 3. a history of cardiovascular disease. The influence of age, sex, social status, and the
perceived quality of the respective doctor-patient-relation on the effects will be examined.
Discussion: To our knowledge, no other published intervention study has yet evaluated the
impact of educating GPs with the goal to treat patients with hypertension according to their global
cardiovascular risk.
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Hypertension management and global cardiovascular risk
Arterial hypertension is a major risk factor for cardiovas-
cular diseases (CVD) such as myocardial infarction and
stroke. The detection and treatment of elevated blood
pressure (BP) and the management of patients with
hypertension is an important challenge of daily practice in
primary care. Previous studies found that only 60% of
patients with known hypertension receive treatment, and
in fewer than 50% of treated patients BP was controlled
below 140/90 mmHg [1-3].
However, recent guidelines on hypertension [4-6], and on
both primary and secondary cardiovascular prevention
[7] emphasise that rather than to focus on single risk fac-
tors, intensity of care should focus on the global cardio-
vascular risk (CVR) of an individual patient. Global
cardiovascular risk is an arithmetical compound of age,
sex, and the known cardiovascular risk factors, and can be
approximated by means of various risk calculators. If
pharmacological risk factor treatment promises a relative
risk reduction of some 25% [8,9], or possibly up to 80%
in combination therapy [10], then a relevant absolute risk
reduction is only possible where there is a relevant abso-
lute risk to begin with. According to the concept of global
cardiovascular risk, therefore, pharmacological treatment
is only recommended for patients with a cardiovascular
10-year-mortality at or above 5%. The essence of this par-
adigmatic change is that treatment efforts and resources
should be concentrated on where the (high) cardiovascu-
lar risk is: "treat risk, not risk factors" [11]. For general
practitioners (GPs), this concept is of particular interest
because it firstly focuses efforts and resources on high-risk
patients, secondly makes GPs and patients more flexible
in the choice of risk-lowering interventions, and thirdly
reassures patients with low CVR that they may not benefit
from treatment despite possible elevated risk factor levels.
Implementing the concept of global CVR for the treatment 
of patients with hypertension
Few studies have been reported [12,13] addressing hyper-
tension management in primary care with explicit consid-
eration of global cardiovascular risk, none of them from
Germany, and none of them measuring CVR before and
after the intervention. The little available data suggest that
GPs are not familiar with the new concept of global cardi-
ovascular risk [14,15].
Initiating a process of behavioural change concerning
guideline adherence of physicians is a challenge. System-
atic reviews of interventions to change professional prac-
tice show that passive dissemination of information has
little or no effect [16]; combined interventions using
audits and feedbacks yield a larger impact, and clinical
outreach visits seem to bring about the largest observed
changes [17]. Outcomes are better if interventions include
active and passive elements of learning, and if they use
individual face-to-face interactions [18].
Objective and research questions
Our general objective is to demonstrate that GPs who
have been made familiar with the concept of global CVR
by means of a complex, tailored intervention will adapt
their treatment accordingly, resulting in measurable
changes in patients' clinical outcomes. In particular, these
are our questions:
1. In a subgroup of patients with high CVR (but no history
of CVD), does a complex educational intervention
directed at the GPs, including an educational outreach
visit, lead to a higher improvement of mean CVR than a
passive intervention, i.e. posting a manual?
2. What are the differential effects of the two interventions
on various clinical targets in three risk-defined subgroups
of patients with hypertension, namely patients with (i) a
history of CVD, (ii) high CVR, but no history of CVD, and
(iii) low CVR?
3. Are the results influenced by patient age, sex, or social
status, or by the perceived quality of the respective doctor-
patient-relationship?
In order to gain a deeper understanding of possible out-
comes and their background, we also conducted an
embedded qualitative study, employing semi-structured
expert interviews in order to explore GPs' views and atti-
tudes towards the new global CVR concept. The corre-




Approval was granted by the Ethics Committee of the
medical faculty of the University of Duesseldorf (no.
2715). Patient consent was not deemed necessary by the
Committee since we use anonymous data routinely col-
lected by GPs.
The trial was registered at ISRCTN44478543.
Design
Prospective non-blinded longitudinal cluster-randomised
intervention study. One GP (or one group practice with
1–3 GPs, respectively) represents a cluster, whereas the
patients are the observation units.
After enrolling the patients, GPs were cluster-randomised
into two groups, A and B. GPs of group A received a writ-
ten manual by mail explaining the concept of global CVR.Page 2 of 7
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vention including a clinical outreach visit (for details cf.
Intervention). GP's of group B received only the written
manual by mail with no further educative intervention.
Thus, the complex intervention (group A) is not com-
pared to usual care, but to a low-level intervention (group
B). This reflects our hypothesis that the benefit of the
complex and therefore more-costly intervention may be
relevant only if the effect can be demonstrated against a
less-complex, low-cost intervention.
Figure 1 is a flow chart of this two-group intervention trial.
Calculation of cardiovascular risk
Global CVR is calculated employing the European SCORE
formula, modified by factor 2 or 3 for men and women,
respectively, with diabetes. We follow the SCORE working
group's definition of a 10-year cardiovascular mortality <
5% for "low" risk, and ≥ 5% for "high" risk in patients
with no history of cardiovascular disease, corresponding
with the 20% dividing line commonly used in cardiovas-
cular morbidity tables [19]. We opt for the SCORE rather
than for the Framingham or PROCAM [20] risk tables
because they are based on data for both men and women,
and retrieved from recent national (German) cohort stud-
ies.
Anticipated dropouts and sample size calculation
Sample size calculation refers to research question 1 (see
above). In order to demonstrate an effect of reducing
mean calculated CVR by a tenth in the subgroup of
patients with high CVR (SCORE ≥ 5%, no history of cardi-
ovascular disease) with a power of 80%, we calculated a
necessary initial sample size of 2 × 51 recruited GPs
enrolling 40 patients each. We estimated a GP drop out
during the enrolment phase of 5%, a patient enrolment
rate of 95%, a GP drop out between baseline and follow
up of a further 5%, and a patient drop out between base-
line and follow up of 10% (resulting in 3146 patients
enrolled by 92 GPs). The sample size calculation was
based on the assumption of a standard deviation of 0.44
for the CVR changes on the log-odds scale, an intra-class
correlation of 0.2 and a proportion of 40% high risk
patients in the total sample, the latter derived from a pilot
study with 330 patients cared for by 20 GPs. According to
these assumptions, 2 × 816 patients were required for the
primary analysis in the high risk group.
Participants and randomisation
We recruited GPs in the district of North-Rhine, choosing
three circumscribed regions close to the cities of Düssel-
dorf, Cologne, and Aachen, one region for each of the
three attending peers (convenience sample).
A random sample of the registered GPs in a given postal
code were invited to participate by fax, and called 3–5
days later by one of the three trained peers. Incentives to
participate were 1. the offer of a free and pharma-inde-
pendent manual and, depending on randomisation, pos-
sibly peer training in a relevant field of General Practice;
2. the opportunity to take part in an innovative research
project developed by GPs for GPs; and 3. an honorarium
of  300 for completing both data surveys (requiring a net
time investment of 5 to 6 hours).
After patient enrolment and baseline data collection, the
GPs (clusters) were randomised to intervention groups A
and B.
In order to avoid the possibility that GPs already familiar
with the concept of global CVR were accidentally over-
represented in either group, we asked the GPs to estimate
the individual CVR of each patient they enrolled. We com-
pared this estimate with the respective patients' calculated
CVR, and divided the GPs into two groups, according to
Flowchartigure 1
Flowchart.
Eligible practices invited to participate 
Practices consenting to participate 
No consent 
Baseline data collection 
GPs asked to enrol consecutively 40 patients each
Cluster - Randomisation 
Intervention A 
50% practices
Manual plus clinical outreach visit
Intervention B 
50% practices
only manual sent by mail 
GP drop out 
Patient drop out
GP drop out 
Patient drop out
Follow up data collection 
6 month after intervention
Follow up data collection 
6 month after intervention
Baseline enrolment  
not completed Page 3 of 7
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CVR. We assumed this division to approximate a measure
for familiarity with the concept of global CVR, and for ran-
domisation, GPs were stratified by this attribute.
Patient enrolment
Every GP was asked to enrol from his or her daily patient
flow a consecutive sample of 40 patients with a known
diagnosis of hypertension, regardless of the cause for con-
sultation. Further inclusion criteria were age 40–75 years,
and continuity of care by this GP over at least six months.
Emergency cases were excepted, and patients expected to
die within 1 year were not included.
Intervention
In order to address the complex issue of hypertension
management in the light of absolute cardiovascular risk,
we developed a multi-faceted intervention through a
process of identifying barriers to implementation, e.g.
comprehensibility of the new concept, and communica-
tion pitfalls. We compiled a written manual (17 pages) on
the basis of the ESC-Guidelines [7] with the following
chapters:
1. Introduction.
2. What is new about the "concept of global CVR?"
3. How to determine global CVR?
4. What is the likely individual benefit of the treatment of
cardiovascular risk factors?
5. Two examples of decision-making.
6. Non-pharmacological therapy: motivation for behav-
ioural change and psychosocial support.
7. Pharmacologic treatment with antihypertensive drugs.
8. Pharmacologic treatment with lipid-lowering drugs.
9. Literature.
This manual was sent by mail to all GPs (randomisation
groups A and B). In addition, GPs in group A received a
personal intervention including an outreach visit by a
peer (30–45 min.), a feedback telephone call after three
weeks (5–10 min.), and delivery of a block of 50 patient
information sheets. Thus, we compared the effect of an
elaborate intervention (A) with the conventional process
of postal dissemination of a guideline-based manual (B),
which is generally assumed to have no or little significant
effect on physician behaviour [16].
During the outreach visit, peer and GP discussed the new
concept on the basis of (a) our manual and (b) 3–4 suita-
ble cases selected by the peer from this GP's baseline data.
The cases were chosen to include at least one patient with
a history of CVD, and at least two patients without such a
history; of the latter one at low risk (SCORE < 5%), and
one at high risk (SCORE > 5%), respectively. The discus-
sion of the GPs' respective patient cases included feedback
elements, and served as concrete examples to demonstrate
the paradigmatic changes of the CVR concept to the GP.
Furthermore, the GPs were instructed how to use the
SCORE calculator of global cardiovascular risk (print ver-
sion, included in the manual), and additional patient
information sheets.
Three practising GPs (TM, AM, and JidS) were trained to
explore GPs' understanding, beliefs, and attitudes during
the initial phase of the conversation in order to tailor the
concept's message to the individual colleague they were
talking to. The process of standardisation was facilitated
by a dialogue draft for the outreach visit, regular audit-
meetings, and personal feedback from a passive observer
who attended the first three visits of each peer.
Our intervention focused on five key messages
1 Therapeutic decisions in the management of hyperten-
sion should always be preceded by an estimation of abso-
lute CVR.
2 Within certain limits, there are no fixed targets for blood
pressure or cholesterol level. Rather, the attainable abso-
lute risk reductions by lowering blood pressure or taking
a statin depend on the absolute CVR before treatment.
3 All patients with manifest cardiovascular diseases
(CVD) are candidates for intensive treatment because of
their very high recurrence risk for CVD. In primary preven-
tion, risk factor treatment should intensify with rising
CVR, whereas patients with low CVR (defined by SCORE
< 5%) have no or little proven benefit from treatment.
4 There are frequently several options to reduce cardiovas-
cular risk. If pharmacological treatment of one risk factor
remains unsatisfactory, e.g. refractory hypertension or
intolerable side effects of anti-hypertensive drugs, then
other options should be considered, such as prescription
of a statin in this patient regardless of a "normal" choles-
terol level.
5 The explanation of individual CVR is meant to enhance
communication between physician and patient, repre-
sents an opportunity to invite the patient to take part in a
process of shared decision making, and can be a poten-
tially powerful vehicle to promote patient autonomy.Page 4 of 7
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Patient enrolment and recording of baseline data took
place before randomisation. Follow up data collection
was conducted 6 to 9 months after the intervention. We
employed a self-developed paper documentation because
of the limited extent and availability of routine computer-
ised data.
At baseline, the documentation on each patient included
age, sex, smoking habits, and history of one or more of the
following: diabetes mellitus, nephropathy, and manifest
cardiovascular disease (namely, coronary artery disease,
cerebrovascular disease, and peripheral artery disease). In
addition, the GPs were requested to indicate drugs rele-
vant for cardiovascular disease, i.e. antihypertensive,
lipid-lowering, and antiplatelet drugs. The actual blood
pressure reading (at enrolment) and the latest cholesterol
measurement (before enrolment) were also noted.
At baseline, GP's were also asked to judge the perceived
quality of the doctor-patient-relationship for each patient,
and to estimate the patient's CVR (as a 10-year-mortality-
risk) on a Likert scale of 1–5.
In addition, we issued a patient questionnaire at baseline
to all enrolled patients asking for CVD family history,
education, physical training, perceived quality of doctor-
patient-relation, personal interest in taking part in treat-
ment decisions, and two questions concerning their
knowledge of global CVR.
At follow-up, actual levels of blood pressure and choles-
terol were documented by practice nurses. New onset of
diabetes mellitus, nephropathy, or cardiovascular events
were recorded. GP's were requested to note any changes in
cardiovascular medical treatment. Smoking status was
updated.
Data Retrieval and Monitoring
Every GP received instruction on study procedures indi-
vidually by one of the three peers. At baseline, data sheets
were directed to GPs only, but at follow-up there were dif-
ferent data sheets for practice nurse and GP, respectively,
restricting the workload of the GPs to data only they could
provide. Data sheets were personally collected by the
peers at baseline, and sent by mail by the GPs at follow-
up. Data were entered into electronic sheets by medical
students. Practice nurses or, where necessary, GPs were
contacted if inconsistencies occurred or to complete miss-
ing data.
In order to monitor the quality of the data submitted by
the GPs at baseline, at the end of the study we issued a
data sheet to the practice nurses requiring them to re-enter
the baseline data for blood pressure and cholesterol from
the electronic record. Since the written baseline data
sheets had been collected from the GPs, we regarded it as
unlikely that the nurses or GPs would recall after follow
up what numbers had been entered at baseline. We will
examine the congruence of the data documented by the
GPs on the baseline forms with the data referring to the
same calendar day entered by the practice nurses some 6–
9 months later.
Incentives for participation
At recruitment, each GP was offered compensation of 
300 for an estimated total workload of at least 6 hours,
plus  40 for the responsible practice nurse. In addition,
practice nurses involved in the monitoring process
received  15 each.
Outcome measures
We will calculate changes in global CVR, mean blood
pressure, total cholesterol, smoking rate, blood pressure
control rate, and prescription rates of CVR-lowering drugs
(ASS and statins).
These outcome measures are to be calculated separately
for three different subgroups of patients defined by their
CVR:
Group I: Patients with a history of manifest cardiovascular
disease (CVD).
Group II: Patients with high CVR (SCORE ≥ 5%), no his-
tory of CVD.
Group III: Patients with low CVR (SCORE < 5%), no his-
tory of CVD.
Statistical analysis
The primary analysis includes all randomised patients of
group II with global CVR determinations at baseline (ITT
population). CVR values at baseline as well as at follow-
up will be transformed on the log-odds scale (multiplica-
tive model). In case of missing follow-up values, a LOCF
(last-observation carried forward) imputation will be per-
formed, i.e. the baseline determination will be imputed as
follow-up determination. For the primary analysis, a two-
level random coefficient model will be fitted to the data
with patients nested in physicians modeled as random
effects. This model takes the correlation structure resulting
from cluster randomisation into account and allows for
differences between physicians in treatment effects. The
primary analysis will compare the baseline-adjusted fol-
low-up means between random groups at a significance
level of 0.05, two-sided.Page 5 of 7
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the complete cases population and for a dataset with miss-
ing values imputed using an EM algorithm.
Secondary analyses will be in the complete cases only.
Analogous to the primary analysis, mixed models will be
fitted for the secondary endpoints in group I, group II and
group III separately.
In the exploratory part of the analysis, the covariates age,
sex, social status, and perceived quality of the respective
doctor-patient-relationship will be added as confounders
and potential effect modifiers to the statistical model. By
backward selection, optimal models will be identified and
reported.
Calculations will be performed with SPSS and STATA, last
available versions.
Discussion
In the past, intervention studies to improve the treatment
of patients with hypertension in General Practice have
focused on educating GPs on how to achieve a maximum
reduction of blood pressure regardless of individual CVR
[21]. Our intervention, in contrast, specifically addresses
patients' individual CVR and may thus lead to varying
therapeutical approaches in patients with different risks,
despite identical blood pressure readings.
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